To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysi...
Many compounding pharmacies use the phrase “bioidentical hormone” as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)–approved menopausal medications that use bioidentical or synthetic hormones or both. Ho...
To provide the evidence-based recommendations on the role of testosterone (T) on age-related symptoms and signs remains. The Italian Society of Andrology and Sexual Medicine (SIAMS) and the and the Italian Society of Endocrinology (SIE) commissioned an expert task force to provide an updated guideline on...
Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence. Perimenopausal and postmenopausal women. Target population will benefit from the most recent published scientific evidence provided via the information from their health care ...
Bhasin, Shalender;
Brito, Juan P;
Cunningham, Glenn R;
Hayes, Frances J;
Hodis, Howard N;
Matsumoto, Alvin M;
Snyder, Peter J;
Swerdloff, Ronald S;
Wu, Frederick C;
Yialamas, Maria A.
Objective
To update the “Testosterone Therapy in Men With Androgen Deficiency Syndromes” guideline published in 2010.
Participants
The participants include an Endocrine Society–appointed task force of 10 medical content experts and a clinical practice guideline methodologist.
Evidence
This eviden...
"OBJECTIVE:
To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults.
PARTICIPANTS:
The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer. The American Association for Clinical Chemistry, the Pituit...
Bourdel, N;
Huchon, C;
Wahab, C. A;
Azaïs, H;
Bendifallah, S;
Bolze, P. A;
Brun, J. L;
Canlorbe, G;
Chauvet, P;
Chereau, E;
Courbiere, B;
Rouge, T. de L. M;
Devouassoux-Shisheboran, M;
Eymerit-Morin, C;
Fauvet, R;
Gauroy, E;
Gauthier, T;
Grynberg, M;
Koskas, M;
Larouzee, E;
Lecointre, L;
Levêque, J;
Margueritte, F;
Mathieu, E D;
Nyangoh-Timoh, K;
Ouldamer, L;
Raad, J;
Raimond, E;
Ramanah, R;
Rolland, L;
Rousset, P;
Rousset-Jablonski, C;
Thomassin-Naggara, I;
Uzan, C;
Zilliox, M;
Daraï, E.
In the Early Stages (ES) of Borderline Ovarian Tumor (BOT), if surgery without risk of tumor rupture is possible, then laparoscopy with protected extraction is recommended over laparotomy (Grade C). In case of bilateral serous ES BOT treatment with a strategy to preserve fertility and/or endocrine functi...
